
Steven Coutre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1638883/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. New England Journal of Medicine, 2014, 371, 213-223.	13.9	1,427
2	lbrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2015, 373, 2425-2437.	13.9	1,261
3	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 2002, 99, 3530-3539.	0.6	1,096
4	United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia. Journal of Clinical Oncology, 2001, 19, 3852-3860.	0.8	773
5	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	13.9	706
6	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2016, 17, 768-778.	5.1	676
7	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 2007, 109, 3207-3213.	0.6	400
8	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet, The, 2020, 395, 1278-1291.	6.3	393
9	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood, 2011, 117, 3294-3301.	0.6	353
10	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood, 2007, 110, 2309-2315.	0.6	349
11	Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, 116, 3751-3757.	0.6	348
12	Single-agent ibrutinib in treatment-naÃ ⁻ ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood, 2018, 131, 1910-1919.	0.6	339
13	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 65-75.	5.1	314
14	Final analysis from RESONATE: Up to six years of followâ€up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 2019, 94, 1353-1363.	2.0	305
15	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2012, 30, 1822-1828.	0.8	287
16	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 2017, 102, 1796-1805.	1.7	200
17	Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. Journal of Clinical Oncology, 2010, 28, 3015-3022.	0.8	181
18	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematology,the, 2017, 4, e114-e126.	2.2	181

#	Article	IF	CITATIONS
19	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood, 2019, 133, 2031-2042.	0.6	178
20	High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2013, 31, 676-683.	0.8	171
21	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood, 2018, 131, 1415-1424.	0.6	160
22	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood, 2018, 131, 1704-1711.	0.6	122
23	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 2017, 129, 2612-2615.	0.6	111
24	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica, 2018, 103, 1502-1510.	1.7	111
25	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 2017, 129, 1763-1767.	0.6	78
26	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology, 2014, 165, 504-509.	1.2	73
27	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naÃ⁻ve chronic lymphocytic leukemia. Leukemia, 2022, 36, 1171-1175.	3.3	72
28	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood, 2018, 131, 2331-2334.	0.6	64
29	Safety Analysis of Four Randomized ControlledÂStudies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 648-657.e15.	0.2	62
30	Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncology, The, 2012, 13, 1096-1104.	5.1	58
31	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 417-423.	0.6	56
32	Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia. Clinical Infectious Diseases, 2022, 74, 1659-1668.	2.9	56
33	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with singleâ€agent ibrutinib. British Journal of Haematology, 2017, 178, 286-291.	1.2	55
34	Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood, 2010, 116, 1777-1777.	0.6	54
35	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 31-31.	0.6	47
36	Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Advances, 2018, 2, 1946-1956.	2.5	40

#	Article	IF	CITATIONS
37	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticÂleukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology, 2018, 182, 504-512.	1.2	37
38	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with allâ€ <i>trans</i> retinoic acid and arsenic trioxide. British Journal of Haematology, 2015, 171, 471-477.	1.2	36
39	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood, 2016, 128, 234-234.	0.6	36
40	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATEâ,,¢-17 Trial. Blood, 2014, 124, 327-327.	0.6	33
41	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 803-813.e7.	0.2	32
42	lbrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. Blood, 2019, 134, 33-33.	0.6	29
43	Outcomes with ibrutinib by line of therapy and postâ€ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 2019, 94, 554-562.	2.0	27
44	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. Blood, 2021, 138, 639-639.	0.6	27
45	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. Blood, 2015, 126, 715-715.	0.6	26
46	Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. British Journal of Haematology, 2007, 136, 379-392.	1.2	25
47	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 3331-3331.	0.6	24
48	Absolute lymphocyte count at day 28 independently predicts eventâ€free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. American Journal of Hematology, 2012, 87, 957-960.	2.0	22
49	A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 1987-1987.	0.6	22
50	Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood, 2018, 131, 2782-2788.	0.6	18
51	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood, 2018, 132, 6-6.	0.6	18
52	Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in Cancer Biology, 2004, 14, 307-315.	4.3	17
53	Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse Blood, 2009, 114, 788-788.	0.6	17
54	Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?. Cancer, 2013, 119, 1186-1194.	2.0	16

#	Article	IF	CITATIONS
55	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. Blood, 2015, 126, LBA-6-LBA-6.	0.6	13
56	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia, 2021, 35, 2854-2861.	3.3	12
57	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATETM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2014, 124, 4696-4696.	0.6	12
58	Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL) Journal of Clinical Oncology, 2015, 33, 7023-7023.	0.8	12
59	CNS Relapse in Acute Promyelocytic Leukemia: Incidence, Management and Outcome. Blood, 2012, 120, 1489-1489.	0.6	12
60	Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood, 2018, 132, 3133-3133.	0.6	11
61	Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. Blood, 2014, 124, 4697-4697.	0.6	11
62	Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy. Blood, 2017, 130, 834-834.	0.6	11
63	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study Journal of Clinical Oncology, 2017, 35, 7510-7510.	0.8	11
64	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with singleâ€agent ibrutinib in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2019, 186, 184-188.	1.2	10
65	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. Blood, 2014, 124, 1990-1990.	0.6	10
66	Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in Cancer Biology, 2004, 14, 23-31.	4.3	9
67	Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials Journal of Clinical Oncology, 2015, 33, e18030-e18030.	0.8	9
68	Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710 Blood, 2006, 108, 566-566.	0.6	7
69	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood, 2016, 128, 4383-4383.	0.6	7
70	Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation Journal of Clinical Oncology, 2015, 33, 7011-7011.	0.8	7
71	Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported Blood, 2009, 114, 1015-1015.	0.6	6
72	A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results. Blood, 2010, 116, 2516-2516.	0.6	6

#	Article	IF	CITATIONS
73	Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. Blood, 2014, 124, 1186-1186.	0.6	6
74	Survival adjusting for crossover: phase 3 study of ibrutinib <i>vs</i> . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica, 2018, 103, e249-e251.	1.7	5
75	Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies. Blood, 2010, 116, 3286-3286.	0.6	5
76	ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Journal of Clinical Oncology, 2019, 37, TPS7566-TPS7566.	0.8	5
77	Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results Blood, 2006, 108, 3770-3770.	0.6	4
78	Performance of the Karius Plasma Next Generation Sequencing Test in Determining the Etiologic Diagnosis of Febrile Neutropenia: Results from a Pilot Study. Open Forum Infectious Diseases, 2017, 4, S613-S614.	0.4	3
79	The Impact of Distance to Treatment Center on the Outcome of AML. Blood, 2010, 116, 4742-4742.	0.6	3
80	Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL) Journal of Clinical Oncology, 2015, 33, 7012-7012.	0.8	3
81	Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM) Journal of Clinical Oncology, 2015, 33, 8532-8532.	0.8	3
82	Myelodysplastic syndromes: disease overview and therapy options. Managed Care, 2008, 17, 3-8.	0.3	3
83	Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. JAAD Case Reports, 2020, 6, 819-821.	0.4	2
84	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-NaÃ ⁻ ve CLL/SLL (RESONATE-2TM). Blood, 2015, 126, 495-495.	0.6	2
85	Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial Journal of Clinical Oncology, 2015, 33, 7016-7016.	0.8	2
86	Classification and Risk Stratification for Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S127-S129.	0.2	1
87	Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines Blood, 2009, 114, 3088-3088.	0.6	1
88	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). Blood, 2010, 116, 1376-1376.	0.6	1
89	Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses. Blood, 2014, 124, 3751-3751.	0.6	1
90	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib Journal of Clinical Oncology, 2019, 37, 7510-7510.	0.8	1

#	Article	IF	CITATIONS
91	Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL. Blood, 2015, 126, 4153-4153.	0.6	1
92	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq0	0 ⁰ 0 ⁶ rgBT	/Overlock 10
93	Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML. Blood, 2020, 136, 36-37.	0.6	1
94	A one-two punch with VO KOs CLL. Blood, 2019, 133, 2737-2738.	0.6	0
95	Pooled Safety Summary for Patients Treated with the CD22-Directed Cytotoxin Moxetumomab Pasudotox-tdfk. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S275.	0.2	0
96	A Phase I Study of a Novel Human Monoclonal Antibody (mAb216) with Chemotherapy for the Treatment of Patients with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia Blood, 2007, 110, 2831-2831.	0.6	0
97	A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2010, 116, 3288-3288.	0.6	0
98	Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status–Based Treatment Stratification. Blood, 2010, 116, 3313-3313.	0.6	0
99	Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk Journal of Clinical Oncology, 2019, 37, 7014-7014.	0.8	0
100	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1580-1588.	0.6	0